Mobile

A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haem...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004879-35

A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety of five escalating doses of NN1731 in haemophilia subjects with inhibitors being treated for acute joint bleeds.

Critère d'inclusion

  • Haemophilia A with anti factor VIII and Haemophilia B with anti factor IX

Liens